An official website of the United States government
Home
Name
Zynlonta
Alternate Names
Loncastuximab tesirine
Abbreviations
None
Category
Biologic therapy (BRM, immunotherapy)
Subcategory
Monoclonal antibody
NSC Number
None
Primary Site
None
Histology
B-cell lymphoma
Remarks
April 23, 2021, The FDA granted accelerated approval to loncastuximab tesirine-lpyl (Zynlonta) a CD19-directed antibody and alkylating agent conjugate, for adult patients with relapsed or refractory large B-cell lymphoma after two or more lines of systemic therapy, including diffuse large B-cell lymphoma (DLBCL) not otherwise specified, DLBCL arising from low grade lymphoma, and high-grade B-cell lymphoma.
Coding
This drug should be coded
